Historical Valuation
Rocket Pharmaceuticals Inc (RCKT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 331.93 is considered Undervalued compared with the five-year average of -7.30. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 64.15 to 67.80 according to relative valuation methord. Compared to the current price of 3.88 USD , Rocket Pharmaceuticals Inc is Undervalued By 93.95%.
Relative Value
Fair Zone
64.15-67.80
Current Price：3.88
93.95%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Rocket Pharmaceuticals Inc (RCKT) has a current Price-to-Book (P/B) ratio of 1.19. Compared to its 3-year average P/B ratio of 3.24 , the current P/B ratio is approximately -63.11% higher. Relative to its 5-year average P/B ratio of 3.47, the current P/B ratio is about -65.64% higher. Rocket Pharmaceuticals Inc (RCKT) has a Forward Free Cash Flow (FCF) yield of approximately -54.16%. Compared to its 3-year average FCF yield of -23.29%, the current FCF yield is approximately 132.48% lower. Relative to its 5-year average FCF yield of -17.73% , the current FCF yield is about 205.51% lower.
P/B
Median3y
3.24
Median5y
3.47
FCF Yield
Median3y
-23.29
Median5y
-17.73
Competitors Valuation Multiple
AI Analysis for RCKT
The average P/S ratio for RCKT competitors is 23705.58, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT.O) exhibits a P/S ratio of 331.93, which is -98.6% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RCKT
1Y
3Y
5Y
Market capitalization of RCKT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RCKT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RCKT currently overvalued or undervalued?
Rocket Pharmaceuticals Inc (RCKT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 331.93 is considered Undervalued compared with the five-year average of -7.30. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 64.15 to 67.80 according to relative valuation methord. Compared to the current price of 3.88 USD , Rocket Pharmaceuticals Inc is Undervalued By 93.95% .
What is Rocket Pharmaceuticals Inc (RCKT) fair value?
RCKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between 64.15 to 67.80 according to relative valuation methord.
How does RCKT's valuation metrics compare to the industry average?
The average P/S ratio for RCKT's competitors is 23705.58, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT) exhibits a P/S ratio of 331.93, which is -98.60% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Rocket Pharmaceuticals Inc (RCKT) as of Jan 10 2026?
As of Jan 10 2026, Rocket Pharmaceuticals Inc (RCKT) has a P/B ratio of 1.19. This indicates that the market values RCKT at 1.19 times its book value.
What is the current FCF Yield for Rocket Pharmaceuticals Inc (RCKT) as of Jan 10 2026?
As of Jan 10 2026, Rocket Pharmaceuticals Inc (RCKT) has a FCF Yield of -54.16%. This means that for every dollar of Rocket Pharmaceuticals Inc’s market capitalization, the company generates -54.16 cents in free cash flow.
What is the current Forward P/E ratio for Rocket Pharmaceuticals Inc (RCKT) as of Jan 10 2026?
As of Jan 10 2026, Rocket Pharmaceuticals Inc (RCKT) has a Forward P/E ratio of -2.14. This means the market is willing to pay $-2.14 for every dollar of Rocket Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Rocket Pharmaceuticals Inc (RCKT) as of Jan 10 2026?
As of Jan 10 2026, Rocket Pharmaceuticals Inc (RCKT) has a Forward P/S ratio of 331.93. This means the market is valuing RCKT at $331.93 for every dollar of expected revenue over the next 12 months.